According to experts, a groundbreaking set of new vaccines for a variety of conditions, including cancer, could save millions of lives.
According to The Guardian, a major pharmaceutical company believes that vaccines for cancer, cardiovascular and autoimmune diseases, and other conditions will be available by 2030.
Studies into these vaccinations are also showing “tremendous promise,” with some researchers claiming that 15 years of progress has been “unspooled” in 12 to 18 months as a result of the Covid jab’s success.
Moderna’s chief medical officer, Paul Burton, believes the company will be able to offer such treatments for “all sorts of disease areas” in as little as five years.
The company, which developed a leading coronavirus vaccine, is now working on cancer vaccines that target various tumour types.
“We will have that vaccine, and it will be highly effective, and it will save hundreds of thousands, if not millions, of lives,” Burton said. I believe we will be able to provide people all over the world with personalised cancer vaccines against a variety of tumour types.”
He also stated that multiple respiratory infections could be covered by a single injection, protecting vulnerable people from Covid, flu, and respiratory syncytial virus (RSV), and that mRNA therapies could be available for rare diseases for which there are currently no drugs, according to the report.
mRNA-based therapies work by instructing cells on how to produce a protein that activates the body’s immune response to disease.
Read More: Alarming TB cases in Pakistan with more than 600,000 cases in 2 Years
The mRNA molecule directs the production of proteins in cells. Cells can pump out proteins that we want our immune system to attack by injecting a synthetic form.
An mRNA-based cancer vaccine would alert the immune system to an existing cancer in a patient’s body, allowing it to attack and destroy it without harming healthy cells.
This entails identifying protein fragments on the surface of cancer cells that are not present on healthy cells and are most likely to elicit an immune response, and then producing mRNA fragments that instruct the body on how to produce them.
First, a biopsy of a patient’s tumour is taken and sent to a lab, where its genetic material is sequenced to identify mutations that aren’t present in healthy cells.
A machine learning algorithm then determines which of these mutations is driving the cancer’s growth.
According to the report, it also learns which parts of the abnormal proteins encoded by these mutations are most likely to elicit an immune response over time. The most promising antigens’ mRNAs are then produced and packaged into a personalised vaccine.
